WO2002045687A2 - Topical alcoholic solution of a salicylic acid derivative and acemannan - Google Patents
Topical alcoholic solution of a salicylic acid derivative and acemannan Download PDFInfo
- Publication number
- WO2002045687A2 WO2002045687A2 PCT/GB2001/005380 GB0105380W WO0245687A2 WO 2002045687 A2 WO2002045687 A2 WO 2002045687A2 GB 0105380 W GB0105380 W GB 0105380W WO 0245687 A2 WO0245687 A2 WO 0245687A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- salicylic acid
- acemannan
- solution
- acid derivative
- physiologically tolerable
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/886—Aloeaceae (Aloe family), e.g. aloe vera
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/12—Aerosols; Foams
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
Definitions
- This invention relates to the use of topically applied salicylic acid derivative compositions in the treatment of herpes zoster in humans, in particular to the use of such compositions which are in liquid form and which further contain aloe vera or acemannan, an active component thereof .
- the virus herpes zoster is a latent form of the virus responsible for chicken pox and causes the intractable and painful skin eruptions known as shingles which afflict many millions of the elderly in particular. Such painful occurrences are known as herpetic neuralgia, e.g. acute herpetic neuralgia and postherpetic neuralgia.
- acetyl salicylic acid is a very well known anti-inflammatory which is normally administered orally in tablet form. While liquid compositions containing ASA, in particular alkanolic solutions of ASA, have been proposed, e.g. for treatment of muscle and joint pain, rheumatism, etc, in recent years liquid ASA formulations have fallen out of favour since ASA is susceptible to hydrolysis producing the irritant salicylic acid.
- topically applied alcoholic solutions of ASA and acemannan are surprisingly effective in combatting herpetic neuralgia, in particular providing a level of pain relief to the patient .
- the invention provides an alcoholic solution of a physiologically tolerable salicylic acid derivative and an acemannan for use in topical treatment of herpetic neuralgia.
- the invention provides the use of a physiologically tolerable salicylic acid derivative, an alcohol and an acemannan for the manufacture of a topically applicable medicament for use in the treatment of herpetic neuralgia.
- the invention provides a method of treatment of herpetic neuralgia in a human subject which method comprises applying to an affected area of the skin of said subject an analgesically effective amount of an alcoholic solution of a physiologically tolerable salicylic acid derivative and an acemannan.
- the salicylic acid derivative used according to the invention may be any physiologically tolerable derivative having analgesic properties.
- the salicylic acid derivative used in the present invention is preferably ASA, or a physiologically tolerable prodrug (e.g. glycolamide) or salt (e.g. a lysine salt) or ester form thereof or an analog thereof (e.g. a 4 or 5 substituted, for example a 4- and/or 5- nitro and/or methoxy acetyl salicylic acid) .
- ASA physiologically tolerable prodrug
- salt e.g. a lysine salt
- ester form thereof e.g. a 4 or 5 substituted, for example a 4- and/or 5- nitro and/or methoxy acetyl salicylic acid
- the salicylic acid derivative if used in salt form, will have as counterion a physiologically tolerable counterion, preferably an amino acid such as lysine.
- a physiologically tolerable counterion preferably an amino acid such as lysine.
- Other tolerable counterions include sodium and meglumine .
- Suitable prodrug forms of ASA include esters which hydrolyse more rapidly in vivo than the acetyl group, e.g. compounds of formula
- R ⁇ is _ 3 alkyl and R 2 is C ⁇ alkyl , 2 -hydroxy-ethyl or -CH 2 CONH 2 , e.g. -CH 2 CON (CH 3 ) 2 , -CH 2 CON (C 2 H 5 ) 2 , -CH 2 CON (iPr) 2 , -CH 2 CON (CH 3 ) CH 2 CH 2 OH and CH 2 CON (CH 3 ) CH 2 CONH 2 .
- Acetyl salicylic acid is especially preferred.
- compositions of the invention also contain acemannan, e.g. in the form of aloe vera. If aloe vera is used, it is preferably used in a pure gel state, although aloe vera in a slightly impure (e.g. at least 98% wt pure) may also be used. Acemannan as such may be used in place of aloe vera.
- compositions of the invention may be in any topically applicable administration form which does not require rubbing of the affected skin, e.g. solutions, emulsions, dispersions, liposomal compositions, sprays, etc.
- the compositions are in the form of solutions or liposome dispersions, particularly solutions .
- compositions may contain transdermal uptake promoters, such as for example dimethylsulphoxide (DMSO) , dimethylformamide, dimethylacetamide, cycloalkanones, etc. (see US-A- 5164416 and EP-A-435436) .
- transdermal uptake promoters such as for example dimethylsulphoxide (DMSO) , dimethylformamide, dimethylacetamide, cycloalkanones, etc. (see US-A- 5164416 and EP-A-435436) .
- compositions contain an alcohol solvent for the salicylic acid derivative, e.g. a C ⁇ _ 6 alkanol, preferably a propanol, especially isopropanol.
- an alcohol solvent for the salicylic acid derivative e.g. a C ⁇ _ 6 alkanol, preferably a propanol, especially isopropanol.
- compositions of the invention preferably also contain a drying agent, e.g. an inorganic salt in anhydrous or partially hydrated form, so as to minimize the water content of the solvent phase .
- a drying agent e.g. an inorganic salt in anhydrous or partially hydrated form
- the drying agent is preferably a porous material which take up water into its pores or by surface adsorption. Alternatively, it may adsorb water by reaction or by hydration of an anhydrous or partially hydrated form of a crystalline substance with stable hydrated forms.
- it may for example be a zeolite, e.g. a zeolite with a pore size of 4A or more, for example up to 10A (or where methanol is used as a solvent, a pore size of 3A) .
- a zeolite having a pore size of up to 6A, more preferably up to 5A, e.g. 3 to 4A will be used.
- Such zeolites are available commercially, e.g.
- silica, alumina or silica-alumina or modified starches e.g. the hydrolysed starch graft copolymers proposed for use in diapers or used in gardening as water retainers - see also GB-A-2009201 and EP-A-74179
- anhydrous or partially hydrated salts such as metal sulphates (e.g. magnesium sulphate or sodium sulphate) may alternatively be used.
- Water retainers e.g.
- modified starches developed in the 1980s by Henkel for diapers and sanitary pads (see the patent publications of Henkel) , and now used in gardening, are typified by "soil-moist", available from Sinclair, Linconshire, UK.
- the water-adsorbers used should preferably be substantially water free when incorporated into the compositions of the invention.
- Particle size is preferably 10 to 4000 ⁇ m, especially 50 to 2000 ⁇ m.
- compositions of the invention further preferably contain a stabilizer, e.g. a polyol or polyalkylene oxide, for example glycerol, polyethyleneglycol, diethyleneglycol, triethyleneglycol, etc.
- a stabilizer e.g. a polyol or polyalkylene oxide, for example glycerol, polyethyleneglycol, diethyleneglycol, triethyleneglycol, etc.
- the lipids used as the liposomal membrane forming molecules are typically phospholipids or hydrogenated phospholipids such as natural or synthetic phosphatidylcholines (lecithins) (PC) , phosphatidylethanolamines (PE) , lysolecithins, lysophosphatidylethanolamines, phosphatidylserines (PS) , phosphatidylglycerols (PG) , phosphatidylinositol (PI) , sphingomyelins, cardiolipin, phosphatidic acids (PA) , fatty acids, gangliosides, glucolipids, glycolipids, mono-, di or triglycerides, ceramides or cerebrosides, e.g. liposome membrane forming compounds such as are described in WO-92/21017.
- PC phosphatidylcholines
- PE phosphatidylethanolamines
- PS phosphat
- the membrane forming lipids may also comprise polymerizable lipids, e.g. methacrylate lipids, thiol and disulphide lipids, dienoate lipids, styryl lipids and diacetylanic lipids as described by Johnston in Liposome Technology Vol. I, Gregoriades Ed., pages 123- 129 (1983) and Singh in Phospholipid Handbook, Cevc Ed., Dekker, pages 233-291 (1993) and references therein.
- the use of polymerizable lipids in the formation of the liposomes provides one route for increasing liposome stability.
- Liposomal compositions may be prepared by conventional means, e.g.
- the continuous phase can if desired be replaced by a continuous phase essentially free of the salicylic acid derivative.
- compositions of the invention will generally be applied directly to the affected skin site, e.g. by spraying or gentle swabbing.
- compositions of the invention are especially preferably applied as sprayed solutions, e.g. from pump action or pressurized spray dispensers.
- Pressurized spray dispensers are especially preferable as access of moisture to the solution during storage before and after first use, and hence hydrolytic breakdown of the salicylic acid derivative, may be avoided.
- Compositions in this format are novel and form a further aspect of the invention. Viewed from this aspect the invention provides a pressurized spray dispenser containing: an essentially anhydrous alkanolic solution of a physiologically tolerable salicylic acid derivative; a propellant; and optionally but preferably an acemannan.
- the propellant will be a compound or compound mixture, generally one which is in gaseous form at one atmosphere pressure at 21°C.
- Halocarbon propellants e.g. CFCs
- Typical suitable propellants include hydrocarbons such as propane and butane .
- compositions of the invention are generally low viscosity, easily sprayed liquids, which can be applied without discomfort to the patient.
- the water content of the alkanol solution is sufficiently low that hydrolysis of the salicylic acid derivative does not occur to a significant extent during storage, e.g. the water content is 2.0% wt or less, preferably 1.0% wt or less.
- the compositions h'erein described are substantially free - from water.
- compositions of the invention preferably contain 1 to 30% wt .
- salicylic acid derivative preferably ASA
- Aloe vera is preferably present at 0.1 to 4% wt, especially 0.4 to 2% wt, particularly 0.7 to 1.5% wt .
- the stabilizer if present, is preferably present at 0.5 to 20% wt, especially 2 to 10% wt, more especially 3 to 6% wt .
- Glycerol is preferably used in this regard.
- the alcohol solvent preferably anhydrous isopropanol
- compositions of the invention are preferably administered in dosages of the salicylic acid derivative of 0.005 to 5 mg/cm 2 skin, especially 0.01 to 1.0 mg/cm 2 .
- compositions of the invention may if desired contain further active ingredients, e.g. antiviral agents, NSAIDs, prostaglandin biosynthesis inhibitors, pain relievers (e.g. lidocaine or other -caine local anaesthetics) , antioxidants, pH modifying agents, skin treatment agents (e.g. ⁇ -hydroxy acids), antimicrobial agents, preservatives, aromas, etc.
- active ingredients e.g. antiviral agents, NSAIDs, prostaglandin biosynthesis inhibitors, pain relievers (e.g. lidocaine or other -caine local anaesthetics) , antioxidants, pH modifying agents, skin treatment agents (e.g. ⁇ -hydroxy acids), antimicrobial agents, preservatives, aromas, etc.
- the compositions however will generally preferably be substantially free from Lowry Bronsted acid components, non-alcohol organic solvents (e.g. ethers, halocarbons, etc.) and ointment bases,
- Aloe vera 1 part by weight
- a solution according to the invention including aloe vera was applied to a 61 year old male, with acute Herpes zoster in the T 3 dermatome, in a lot of pain.
- a numeric rating scale from 11- 0, where 11 is great pain
- after application the following hour he rated it to 4.
- the skin-inflammation was greatly reduced, and the pain was reduced on the NR3 to 2-3.
- a solution according to the invention excluding aloe vera was applied to a 37 old female, with acute Herpes simplex on a Labia majora, in pain. After 20 minutes she enjoyed full relief of pain, but she had to apply the spray every hour in 6 hours to get continuous pain relief. The inflammation was totally gone after 25 hours .
Abstract
Description
Claims
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2002218419A AU2002218419A1 (en) | 2000-12-05 | 2001-12-05 | Topical alcoholic solution of a salicylic acid derivative and acemannan |
EP01999356A EP1349540A2 (en) | 2000-12-05 | 2001-12-05 | Topical alcoholic solution of a salicylic acid derivative and acemannan |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB0029634.3 | 2000-12-05 | ||
GBGB0029634.3A GB0029634D0 (en) | 2000-12-05 | 2000-12-05 | Use |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2002045687A2 true WO2002045687A2 (en) | 2002-06-13 |
WO2002045687A3 WO2002045687A3 (en) | 2003-04-10 |
Family
ID=9904475
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/GB2001/005380 WO2002045687A2 (en) | 2000-12-05 | 2001-12-05 | Topical alcoholic solution of a salicylic acid derivative and acemannan |
Country Status (4)
Country | Link |
---|---|
EP (1) | EP1349540A2 (en) |
AU (1) | AU2002218419A1 (en) |
GB (1) | GB0029634D0 (en) |
WO (1) | WO2002045687A2 (en) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1534235A1 (en) * | 2002-06-25 | 2005-06-01 | Acrux DDS Pty Ltd | Transdermal delivery rate control using amorphous pharmaceutical compositions |
EP1716855A1 (en) * | 2004-02-16 | 2006-11-02 | Teikoku Seiyaku Co., Ltd. | Remedy for external use for skin and mucosal injuries caused by viral infection |
FR3130556A1 (en) * | 2021-12-16 | 2023-06-23 | L'oreal | Use of salicylic acid and/or its derivatives and/or their salts, for increasing or restoring cutaneous tactile perception |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4219548A (en) * | 1978-09-01 | 1980-08-26 | The Procter & Gamble Company | Topical anti-inflammatory composition |
US4942031A (en) * | 1988-02-23 | 1990-07-17 | Levin Robert H | Compositions containing LYCD and other topically active medicinal ingredients |
EP0405299A2 (en) * | 1989-06-23 | 1991-01-02 | Giuseppe De Benedittis | Composition for the treatment of acute herpetic neuralgia and post-herpetic neuralgia |
US5034221A (en) * | 1989-06-22 | 1991-07-23 | Rosen Steven E | Topical agent and method for the treatment of Pseudofolliculitis barbae |
WO1993021899A1 (en) * | 1992-05-05 | 1993-11-11 | The Procter & Gamble Company | Acne treating composition |
US5736126A (en) * | 1996-03-15 | 1998-04-07 | Van Engelen; H. Wayne | Liquid transdermal analgesic |
WO2000078354A1 (en) * | 1999-06-22 | 2000-12-28 | Norway Medical Group Int As | Topical composition comprising acetyl salicylic acid |
-
2000
- 2000-12-05 GB GBGB0029634.3A patent/GB0029634D0/en not_active Ceased
-
2001
- 2001-12-05 EP EP01999356A patent/EP1349540A2/en not_active Withdrawn
- 2001-12-05 AU AU2002218419A patent/AU2002218419A1/en not_active Abandoned
- 2001-12-05 WO PCT/GB2001/005380 patent/WO2002045687A2/en not_active Application Discontinuation
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4219548A (en) * | 1978-09-01 | 1980-08-26 | The Procter & Gamble Company | Topical anti-inflammatory composition |
US4942031A (en) * | 1988-02-23 | 1990-07-17 | Levin Robert H | Compositions containing LYCD and other topically active medicinal ingredients |
US5034221A (en) * | 1989-06-22 | 1991-07-23 | Rosen Steven E | Topical agent and method for the treatment of Pseudofolliculitis barbae |
EP0405299A2 (en) * | 1989-06-23 | 1991-01-02 | Giuseppe De Benedittis | Composition for the treatment of acute herpetic neuralgia and post-herpetic neuralgia |
WO1993021899A1 (en) * | 1992-05-05 | 1993-11-11 | The Procter & Gamble Company | Acne treating composition |
US5736126A (en) * | 1996-03-15 | 1998-04-07 | Van Engelen; H. Wayne | Liquid transdermal analgesic |
WO2000078354A1 (en) * | 1999-06-22 | 2000-12-28 | Norway Medical Group Int As | Topical composition comprising acetyl salicylic acid |
Non-Patent Citations (2)
Title |
---|
See also references of EP1349540A2 * |
SWERDLOW M: "TOPICAL APPLICATIONS FOR PAIN THERAPY IN POST-HERPETIC NEURALGIA" PAIN CLINIC, VNU, UTRECHT, NL, vol. 6, no. 3, 1993, pages 153-156, XP001057955 ISSN: 0169-1112 * |
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1534235A1 (en) * | 2002-06-25 | 2005-06-01 | Acrux DDS Pty Ltd | Transdermal delivery rate control using amorphous pharmaceutical compositions |
EP2266533A3 (en) * | 2002-06-25 | 2011-12-14 | Acrux DDS Pty Ltd | Transdermal delivery rate control using amorphous pharmaceutical compositions |
US8357393B2 (en) | 2002-06-25 | 2013-01-22 | Acrux Dds Pty Ltd. | Transdermal delivery rate control using amorphous pharmaceutical compositions |
US8784878B2 (en) | 2002-06-25 | 2014-07-22 | Acrux DDS Pty Ltc. | Transdermal delivery rate control using amorphous pharmaceutical compositions |
EP1534235B1 (en) * | 2002-06-25 | 2016-07-27 | Acrux DDS Pty Ltd | Transdermal delivery rate control using amorphous pharmaceutical compositions |
EP1716855A1 (en) * | 2004-02-16 | 2006-11-02 | Teikoku Seiyaku Co., Ltd. | Remedy for external use for skin and mucosal injuries caused by viral infection |
EP1716855A4 (en) * | 2004-02-16 | 2008-06-18 | Teikoku Seiyaku Kk | Remedy for external use for skin and mucosal injuries caused by viral infection |
FR3130556A1 (en) * | 2021-12-16 | 2023-06-23 | L'oreal | Use of salicylic acid and/or its derivatives and/or their salts, for increasing or restoring cutaneous tactile perception |
Also Published As
Publication number | Publication date |
---|---|
EP1349540A2 (en) | 2003-10-08 |
AU2002218419A1 (en) | 2002-06-18 |
WO2002045687A3 (en) | 2003-04-10 |
GB0029634D0 (en) | 2001-01-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ES2207023T3 (en) | COMPOSITIONS THAT INCLUDE A COMBINATION OF A FREE SPPHINGOID BASE AND A CERAMIDE AND USE OF THE SAME. | |
JP4555111B2 (en) | With improved deformability, including at least three amphiphiles for improved transport through a semipermeable barrier and for non-invasive drug utilization in vivo, especially through the skin Agglomerates | |
EA027038B1 (en) | Foam formulations containing at least one triterpenoid | |
US5045559A (en) | Treatment of skin disorders | |
CA2726538A1 (en) | Foam skin care cream | |
US20080076831A1 (en) | Hemorrhoid reliever and method of use | |
ITMI20070644A1 (en) | TOPIC COMPOSITIONS INCLUDING MAGALDRATE | |
ZA200304635B (en) | Hypoallergenic and non-irritant skin care formulations. | |
WO2002045687A2 (en) | Topical alcoholic solution of a salicylic acid derivative and acemannan | |
SK284505B6 (en) | Use of a combination of a diol and an alpha-hydroxy acid in a vehicle for the preparation of a medicament for the topical treatment of hyperkeratotic skin diseases | |
US8529915B2 (en) | (R)-(-)-1,2-propanediol compositions and methods | |
US8821904B2 (en) | Topical composition and use thereof for the prophylaxis and the treatment of defects connected to inflammatory dermopathies | |
ITRM930365A1 (en) | USE OF L-CARNITINE ESTERS ON OXYDRIDE WITH AROMATIC ACIDS TO PRODUCE PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF SKIN DISEASES. | |
KR100527346B1 (en) | multilamellar emulsion cosmetics containing pseudoceramides | |
EP1146844B1 (en) | Membrane lipid compositions | |
EP0525655A1 (en) | Formulations useful for vaginal dryness treatment | |
US20150105349A1 (en) | (R)-(-)-1,2-propanediol compositions and methods | |
ES2225837T3 (en) | 2,3-DIARIL-1-BENZOPIRANS FOR THE TREATMENT OF DERMATITIS. | |
WO1998010768A1 (en) | Antiviral compositions | |
EP0834312B1 (en) | Topical medicament containing diclofenac | |
KR102015890B1 (en) | Polysaccharide liquid crystal composition and manufacturing method thereof and cosmetic composition comprising the same | |
CA2299298A1 (en) | Compositions for nasal administration | |
EP1341515B1 (en) | Water-free skin care formulations comprising micronized urea and method of manufacturing the same | |
EP4342450A1 (en) | Hydroalcoholic topical diclofenac formulations | |
CA2341566C (en) | Use of lithium gluconate for making a medicine for treating herpes and seborrheic dermatitis |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ CZ DE DE DK DK DM DZ EC EE EE ES FI FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2001999356 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2002218419 Country of ref document: AU |
|
WWP | Wipo information: published in national office |
Ref document number: 2001999356 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 2001999356 Country of ref document: EP |
|
NENP | Non-entry into the national phase in: |
Ref country code: JP |
|
WWW | Wipo information: withdrawn in national office |
Country of ref document: JP |